HIMS Slides 8% Into Tonight's Q1 Print as Friday's Squeeze Unwinds

The Unwind Into the Binary

HIMS is trading at $28.73, down 8.17% over 24 hours, with Q1 2026 results due after the close tonight. Two sessions ago the stock printed $31.24 on an 18% squeeze — JPMorgan's $35 Overweight, the Novo Nordisk patent-suit dropout, and the peptide-rule loosening had stacked the long side into the print. That positioning is now coming off. The average analyst price target sits at $27.25, below where the stock is trading even after today's move, and the desks pricing this earnings cycle are using a roughly 13–16% implied straddle through the May 15 expiration. When the implied move is bigger than the YTD performance gap, longs that bought the rumor sell it before the tape hits. That is what today looks like.

Why Tonight's Number Is Already Half-Known

The setup is unusually transparent. Consensus from 11 analysts has parked at $0.03 EPS on $616.9M of revenue for the last 30 days, with the 90-day EPS estimate revised down 78.6% from $0.14. That implies an 85% year-over-year earnings collapse against Q1 2025's $0.20 print on revenue growth of just 5.2% — a brutal deceleration from the 111% top-line expansion HIMS delivered in the same quarter last year. The reason matters: HIMS is absorbing margin pressure as it transitions away from compounded GLP-1s toward higher-cost branded inventory. The Novo Nordisk deal granting HIMS distribution of branded Wegovy and Ozempic only went live on March 26, five days before the quarter ended. Whatever HIMS prints tonight on the GLP-1 line, it is not the deal everyone is repricing the stock around — that's a Q2 number.

What Makes the Print Binary

The structural setup hasn't changed: HIMS still carries short interest near 34% of float, a $250M buyback live, and a subscriber base management has guided above 2.5M. The asymmetry is in what management says, not what they earned. A subscribers-above-expectations print with a clean Q2 ramp guide for branded GLP-1 unit economics reignites the squeeze that broke the 200-week moving average in April. A subscriber miss with margin guidance that confirms the Wegovy/Ozempic distribution take rate is structurally dilutive validates the bear case that has HIMS heading back toward $10 without a beat. Today's 8% de-risk is the market refusing to be long either side into a number where the consensus EPS already assumes the worst is happening. The tape after 4:05 ET decides whether the spring re-rate was the bottom or the trap.